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Background and Purpose: The theophylline in acute ischemic stroke trial investigated
the neuroprotective effect of theophylline as an add-on to thrombolytic therapy in patients
with acute ischemic stroke. The aim of this pre-planned subgroup analysis was to use
predictive modeling to virtually test for differences in the follow-up lesion volumes.
Materials and Methods: A subgroup of 52 patients from the theophylline in acute
ischemic stroke trial with multi-parametric MRI data acquired at baseline and at 24-h
follow-up were analyzed. A machine learning model using voxel-by-voxel information
from diffusion- and perfusion-weighted MRI and clinical parameters was used to predict
the infarct volume for each individual patient and both treatment arms. After training
of the two predictive models, two virtual lesion outcomes were available for each
patient, one lesion predicted for theophylline treatment and one lesion predicted for
placebo treatment.
Results: The mean predicted volume of follow-up lesions was 11.4ml (standard
deviation 18.7) for patients virtually treated with theophylline and 11.2ml (standard
deviation 17.3) for patients virtually treated with placebo (p = 0.86).
Conclusions: The predicted follow-up brain lesions for each patient were not
significantly different for patients virtually treated with theophylline or placebo, as an
add-on to thrombolytic therapy. Thus, this study confirmed the lack of neuroprotective
effect of theophylline shown in the main clinical trial and is contrary to the results from
preclinical stroke models.
Keywords: stroke, thrombolytic therapy, clinical trial, theophylline, reperfusion, machine learning, neuroprotective
drugs
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INTRODUCTION
The vasoactive agent theophylline has shown promising
neuroprotective effects with reduced brain tissue edema, brain
damage, and mortality in animal stroke models (1–3) but the
results were controversial in previous randomized clinical
trials (4, 5). The theophylline in acute ischemic stroke trial
was designed to overcome the limitations of previous trials,
namely the lack of acute ischemic stroke validation, lack of
revascularization therapy, and delayed intervention (6). A total
of 64 patients with acute ischemic stroke verified with MRI
were randomized to a single infusion of 220mg theophylline or
placebo as an add-on to thrombolytic therapy. The co-primary
endpoint of early clinical improvement, defined as change of
the NIHSS score from baseline to follow-up at 24 h, improved
by 4.7 points (standard deviation [SD] 5.6) in the theophylline
group compared with an improvement of 1.3 points (SD 7.5)
in the group treated with thrombolytic therapy alone (p =
0.04) (7). The co-primary endpoint of infarct growth at 24-h
follow-up was 141.6% (SD 126.5) in the theophylline group
and 104.1% (SD 62.5) in the control group (p = 0.15). While
the clinical endpoint alone would have shown statistically
significant early improvement, it was considered not statistically
significant after correcting for multiple testing due to two
primary endpoints. With respect to the imaging endpoint,
comparing two independent groups with small sample size
exhibiting a large variation of stroke lesion volumes might have
prevented the detection of a small effect of theophylline. For
that reason, a machine learning approach to predict follow-up
lesions was pre-planned as a subgroup analysis. The basic idea
of this method is to train two machine learning models based
on imaging data on a voxel-wise basis acquired at the acute
stage and the known follow-up lesion information. Thus, two
predicted volumes of follow-up lesions can be quantified for each
individual patient, one lesion outcome for the virtual treatment
with theophylline and one lesion for the virtual treatment with
placebo, which practically doubles the outcome measurements
that can be used for statistical testing.
The aim of this study was to use this predictive modeling
approach to compare follow-up lesion volumes of patients
treated virtually with theophylline and placebo as an add-on to
thrombolytic therapy to investigate if there is a subtle treatment
effect of theophylline within individual patients that was not
obvious when comparing the lesion volumes in the small groups.
MATERIALS AND METHODS
Anonymized data that support the findings of this
study are available from the corresponding author upon
reasonable request.
Study Design
The present study is based on a subgroup of the theophylline
in acute ischemic stroke trial, a current proof-of-concept,
randomized, double-blinded, placebo-controlled trial that
assessed the neuroprotective effect of theophylline as an add-on
to thrombolytic therapy. The trial was registered at the European
Union Drug Regulating Authorities Clinical Trials Database
(EudraCT number 2013-001989-42). The trial protocol was
approved by the Danish Health and Medicines Authorities (ref.
no. 2013050908) and the Regional Scientific Ethic Committee
(ref.-no. N-20130034) (6). Written informed consent was
obtained from all patients and the trial was conducted in
compliance with the Declaration of Helsinki. The trial was
terminated early due to slow recruitment.
Definition of Subgroup
The main selection criterion for the theophylline in acute
ischemic stroke trial was eligibility for thrombolytic therapy
within 4.5 h of symptom onset in patients with MRI verified
moderate to severe acute ischemic stroke (NIHSS ≥4). For
this pre-planned subgroup analysis, all patients with multi-
parametric MRI including diffusion- and perfusion-weighted
MRI at baseline, and available 24-h follow-upMRI were analyzed.
Image Acquisition
All patients underwent MRI with the same field strength (1.5 or
3.0 Tesla) at admission (baseline) and at 24-h (22–32-h) follow-
up. The MR sequences included diffusion-weighted MRI (DWI),
perfusion-weighted MRI (PWI) with intravenous gadolinium
(0.1 mmol per kilogram body weight, 5 ml/s bolus injection),
circle of Willis time-of-flight MR angiography, gradient echo
weighted MRI, and T2-FLAIR MRI. The thrombolysis in
myocardial infarction (TIMI) grading was used to grade arterial
obstruction (8). TIMI 0-1 at baseline was defined as large vessel
occlusion and TIMI 0-1 at baseline converted to 3-4 at 24-h
follow-up was defined as revascularization.
Image Post-processing
Post-processing of DWI and PWI was performed semi-
automatically using the AnToNIa software tool to extract voxel-
by-voxel information for training of themachine learningmodels
(9). In detail, the following processing steps were applied: An
apparent diffusion coefficient dataset was calculated based on
two DWI datasets (b-value = 0 and b-value,= 1,000 mm²/s).
The ADC map was used for an automatic thresholding-based
brain tissue and cerebrospinal fluid segmentation. The baseline
ischemic core was manually delineated using a semi-automatic
volume growing approach with an upper ADC threshold of
550 × 10−6 mm²/s, in accordance to a previous stroke study
(10). The delineated ischemic core was then used to compute
a distance map displaying the Euclidean distance for each non-
core voxel to the closest voxel of the ischemic core. This was
done to incorporate prior knowledge that the probability of
final tissue infarction decreases with distance to the infarct
core into the machine learning model. The PWI dataset was
automatically motion corrected and the arterial input function
was manually defined at the ICA or MCAM1-segment. A block-
circulant deconvolution-based perfusion analysis was used to
calculate the cerebral blood flow, cerebral blood volume, mean
transit time, and time-to-maximum of the residual function
(Tmax). Mean values were determined for each parameter in
the contralateral brain tissue (excluding cerebrospinal fluid)
and used for normalization of the perfusion parameters (CBF
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and CBV values by calculating the ratio, MTT and Tmax by
subtraction of the contralateral average values). The normalized
Tmax perfusion parameter maps were segmented using a lower
threshold of 6 s to determine the hypoperfused tissue. The
PWI parameter maps were automatically registered to the ADC
dataset and the tissue at risk was calculated by subtracting the
ADC lesion from the Tmax (>6 s) hypoperfusion. Information
about the localization of each voxel and possible regional
vulnerability to ischemia was added by registering the Montreal
Neurological Institute brain atlas to each ADC dataset, described
in more details by Forkert et al. (9). The ipsilateral follow-up
brain tissue lesion was manually segmented in the follow-up T2-
FLAIR dataset of each patient acquired at 24-h using the software
tool ITK-SNAP (v. 3.6.0) (11) and registered to the baseline ADC
dataset. The imaging data were complemented by the following
clinical parameters: age, sex, baseline NIHSS, and time of stroke
onset to theophylline / placebo application.
Finally, 12 equally weighted features were available for
each voxel: Tissue type probability, anatomical location,
distance to the ischemic core, ADC value, CBF value,
CBV value, MTT value, Tmax value, and the four clinical
parameters as well as information about the infarct outcome.
A stratified, under-sampled training set consisting of all voxels
from the follow-up infarct lesion and an equal number of
non-lesion voxels randomly sampled from the ipsilateral
hemisphere were extracted for each dataset. This approach and
feature setup yielded the best results in a previous in-depth
technical evaluation (12).
Lesion Outcome Prediction
Two random forest machine learning models were trained, one
using all training sets from the patients treated with theophylline
and one using all training sets from the patients treated with
placebo. The patient in whom the algorithm was tested (used
for lesion outcome prediction) in each iteration was always
excluded from the aggregated training set used for training of
the random forest models. Practically, the machine learning
models were implemented using ALGLIB (www.alglib.net) (13)
with the random forest model consisting of 100 trees assuring
an acceptable compromise between accuracy and computation
speed, described in more details by Winder et al. (12).
After training of the two predictive models, both models were
used to predict the lesion outcome for both treatment options for
each patient.
Statistical Analyses
Baseline characteristics are presented by the mean ± standard
deviation or median and interquartile range, as appropriate.
Continuous data were compared with Wilcoxon’s rank sum test.
Categorical data were summarized by counts and percentages
and compared using Fisher’s exact test. For the primary endpoint,
a paired t-test was used to compare the predicted volumes
of the follow-up lesion for each patient virtually treated with
theophylline or placebo and the data was represented as box-
whisker graph. Dice similarity coefficients comparing the true
lesion outcome with the predicted lesion outcome within each
group were calculated to quantify the prediction accuracy.
Furthermore, the difference and average of both predictions for
each patient were calculated and presented using a Bland Altman
plot. For the additional explorative analysis, an unpaired t-test
was used to compare the difference between the two predicted
lesion volumes for patients with and without presence of tissue at
risk at baseline, for patients with cortical vs. lacunar infarction,
for patients with large vessel occlusion at baseline, and for
patients with recanalization at follow-up.
All tests were applied as post-hoc analysis with a two-sided
alpha level of 0.05 without correction for multiple comparisons.




MRI including baseline DWI and PWI and follow-up T2-FLAIR
at 24 h was available in 52 out of 64 patients included in the main
study (43 patients imaged at 3.0 Tesla and 9 patients imaged at
1.5 Tesla MRI field strength). Overall, the baseline characteristics
were similar between the two treatment groups (Table 1).
However, diabetes mellitus was more frequently present in the
control group (four patients) compared to the theophylline group
(no patients). The process measures: time of stroke onset to door,
door to thrombolysis, door to theophylline/placebo treatment,
and the rate of additional endovascular therapy were similar
between the two treatment groups. Likewise, the baseline imaging
characteristics volume of ischemic core, volume of tissue-at-
risk, type of vessel occlusion, and grade of vessel occlusion were
similar between the two treatment groups. The mean volume of
ischemic lesion based on the segmentation of the follow-up T2-
FLAIR dataset at 24-h was 13.9ml (SD 20.3) for the theophylline
group and 11.7ml (SD 19.3) for the placebo group (p= 0.92).
Primary Outcome
The mean Dice similarity coefficient was 0.40 (SD 0.249) for
the theophylline prediction model and 0.35 (SD 0.243) for the
placebo prediction model, which is in the range of previously
described methods (12).
Using the two predictive models, the mean predicted lesion
volume was 11.4ml (standard deviation (SD) 18.7) for the
patients virtually treated with theophylline and 11.2ml (SD
17.3) for patients virtually treated with placebo (Figure 1). No
significant difference was found between the predicted volumes
of the two treatment groups using a paired t-test (p = 0.86). A
detailed list of the true and predicted lesion volumes for each
individual patient is provided as Supplementary Table 1.
Additional Analyses
The predicted lesion volumes for each patient virtually treated
with theophylline or placebo were similar for small and
large infarct volumes as illustrated in the Bland-Altman plot
(Figure 2). Tissue-at-risk at baseline was present in 29 patients
and absent in 23 patients. The type of stroke was classified
as cortical in 34 patients and lacunar in 18 patients. Twenty-
three patients fulfilled the criteria for large vessel occlusion at
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TABLE 1 | Baseline characteristics.
Theophylline group (N = 27) Control group (N = 25) p-value
Clinical
Median age – year (IQR) 71 (55–77) 69 (52–78) 0.86
Female sex – no. (%) 10 (37) 11 (44) 0.61
Median NIHSS score (IQR) 8 (6–13) 7 (6–8) 0.12
Hypertension – no. (%) 14 (52) 16 (64) 0.38
Diabetes mellitus – no. (%) 0 (0) 4 (8) 0.03
Hyperlipidemia – no. (%) 16 (59) 16 (64) 0.73
Arterial fibrillation – no. (%) 2 (7) 4 (16) 0.33
Peripheral arterial disease – no. (%) 2 (7) 0 (0) 0.16
Previous myocardial infarction – no. (%) 1 (4) 1 (4) 0.96
Previous transitory ischemic attack – no. (%) 2 (7) 2 (8) 0.94
Previous stroke – no. (%) 3 (11) 3 (12) 0.92
Previous intracranial hemorrhage – no. (%) 0 (0) 0 (0) 1
Current smoking – no. (%) 10 (37) 9 (36) 0.94
Antiplatelet agent – no. (%) 7 (26) 9 (36) 0.43
Imaging characteristics
Mean volume of ischemic core – ml (SD) 4.4 (6.4) 4.3 (7.8) 0.81
Mean volume of baseline tissue at risk – ml (SD) 9.6 (22.0) 6.5 (13.9) 0.44
Large vessel occlusion – no. (%) 12 (44) 11 (44) 0.97
Type of vessel occlusion 0.85
Anterior cerebral artery – no. (%) 0 (0) 1 (4)
Middle cerebral artery (M1-segment) – no. (%) 6 (22) 4 (16)
Middle cerebral artery (M2-3-segment) – no. (%) 5 (19) 5 (20)
Posterior cerebral artery – no. (%) 1 (4) 1 (4)
No visible large vessel occlusion – no. (%) 15 (55) 14 (56)
Grade of vessel occlusion at baseline 0.97
TIMI-score 0–1 – no. (%) 12 (44) 11 (44)
TIMI-score 2–3 – no. (%) 15 (56) 14 (56)
Process measures
Median stroke onset – door time – min (IQR) 81 (48–148) 85 (68–130) 0.41
Median door to thrombolysis-time – min (IQR) 39 (35–45) 41 (35–51) 0.75
Additional endovascular therapy – no. (%) 3 (11) 4 (16) 0.61
The baseline characteristics of the two groups were not significantly different apart from diabetes mellitus (p = 0.03).
IQR, Interquartile range; SD, Standard deviation; NIHSS, National Institute of Health Stroke Scale; TIMI, thrombolysis in myocardial infarction grading of arterial obstruction (score zero,
complete occlusion; one, severe stenosis; two, mild to moderate stenosis; three, normal arterial caliber).
baseline (TIMI 0-1), and the criteria for recanalization at follow-
up (TIMI 3-4) were fulfilled in 10 out of these 23 patients.
The predicted follow-up lesions were not significantly different
between patients with and without presence of tissue-at-risk
at baseline (p = 0.89), in patients with cortical vs. lacunar
infarction (p = 0.88), in patients with and without large vessel
occlusion at baseline (p= 0.57), and in patients with and without
recanalization at follow-up (p= 0.35) (Figure 3).
DISCUSSION
Themain finding of this secondary analysis of the theophylline in
acute ischemic stroke trial is that the predicted follow-up lesion
volumes of patients virtually treated with theophylline or placebo
are not significantly different.
The primary aim of the theophylline in acute ischemic stroke
trial was to investigate the neuroprotective effect of theophylline
as an add-on to thrombolytic therapy in patients with acute
ischemic stroke. The clinical endpoint alone would have shown
a statistically significant early improvement at 24-h follow-up
(p = 0.04) but was considered not statistically significant after
correcting for multiple testing due to two primary endpoints. The
co-primary endpoint infarct growth did not reach significance
(p = 0.19). However, it was uncertain whether the considerable
variation of stroke lesion volumes in a small sample size and the
infarct growth information limited to the follow-up T2-FLAIR
segmentation might have prevented detection of a subtle effect
of theophylline. The rather small infarct volumes and the large
variation in a small sample size was the main motivation for
this post-hoc analysis using a predictive modeling approach for
a more in-depth comparison of the groups. Various machine
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learning models have been presented in the past for this
purpose typically showing better performance for tissue outcome
prediction compared to simple perfusion parameter thresholding
(14–17). A recent study showed that such machine learning
models cannot only be used to predict the lesion outcome
FIGURE 1 | Predicted volume of follow-up lesions. Box-whisker diagram
depicting the mean predicted volumes of follow-up lesions based on the
trainings datasets of patients treated with theophylline and placebo:
Interquartile range with median (box), lower and upper interquartile +1.5
interquartile range (whisker), and outliers (dots).
in patients for treatment decision making but also for intra-
individual virtual comparisons of treatments (18). This voxel-
by-voxel analysis of eight imaging parameters for each voxel
based on DWI and PWI sequences collected from each patient
together with four clinical parameters practically allows to double
the sample size by simulating both treatment outcomes for each
patient included in this study. The accuracy of the prediction
models was acceptable as the mean Dice similarity coefficients
comparing the true lesion volumes with the predicted lesion
volumes within each group were within the range of results
from a recent study applying multi-parametric tissue outcome
prediction methods (12).
In our trial, the surrogate marker for follow-up lesion
volume was almost identical for patients virtually treated with
theophylline and patients virtually treated with placebo. Thus, the
machine learning approach with practically doubled sample size
of outcome measurements compared to the main clinical trial
confirmed the lack of a neuroprotective effect of theophylline.
This is most notably true, as there is no detectible neuroprotective
effect on infarct growth in the highly selected subgroup of
patients with presence of tissue-at-risk at baseline and/or
subsequent recanalization. One limitation of this study is that
the small sample size did not allow a sufficient investigation of a
lesion-size dependent effect of theophylline although the Bland
Altman plots as well as a simple evaluation using regression
analysis do not suggest such an effect. Although all perfusionMRI
were sufficient for analysis, and complete follow-up was available,
the main limitation remains the low number of patients in this
FIGURE 2 | Interaction of infarct size and prediction. Bland Altman plot depicting the predicted volume of follow-up lesions plotted as the difference between the two
predictions (theophylline and placebo) over the average of the two predicted volumes for each patient: Values <0 indicate that theophylline is better than placebo
while values >0 indicate that placebo is better than theophylline: Middle line indicates mean difference between the predicted values, upper and lower line indicates
the higher and lower limit of agreement (2x standard deviation) indicating no significant difference between small and large infarct volumes.
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FIGURE 3 | Subgroup analysis. Box-whisker diagrams depicting the predicted volume of follow-up lesions plotted as the difference between the two predictions
(theophylline and placebo) for each patient: Values <0 indicate that theophylline is better than placebo and values >0 indicate that placebo is better than theophylline
indicating no significant difference for patients with and without tissue-at-risk at baseline, for patients with cortical vs. lacunar infarction, for patients with and without
large vessel occlusion at baseline, and for patients with and without recanalization at follow-up.
subgroup analysis. However, previous work has shown that the
machine learning model used requires no more than 50 datasets
for optimal training (19). Accordingly, the Dice scores achieved
in our study were within the range of previously published
papers. Another limitation is that machine learning models are
rarely employed in clinical trials. As discussed by Fiehler et al.
(18), the potential of a study design with virtual comparators
based on predictive modeling is highly informative, quick, and
relatively inexpensive. In contrast to that, the established study
design of a randomized control trial provides the highest level
of evidence. In our study, application of a machine learning
model allowed further insights given the limited dataset and
confirmed the results of the main trial. However, the large
variation of lesions, the variation of infarct types with and
without collateral supply, and the large variation or lack of tissue-
at-risk are still relevant limitations of this study. Nevertheless, we
believe that predictive modeling to virtually test for differences
in the follow-up lesion volumes can become an essential tool to
support conventional trials in acute ischemic stroke by enabling
an improved evaluation of evidence on intermediate outcomes
and to increase the sample size for the primary or secondary
outcomes in case of underpowered studies.
There is no known interaction between theophylline
and alteplase. Recently, such interaction was observed to
inhibit the neuroprotective effect of Nerinetide in acute
ischemic stroke in the ESCAPE-NA1-trial. In that trial,
Nerinetide did not improve the good clinical outcomes after
endovascular thrombectomy (20).
In line with numerous previous neuroprotective clinical
trials, our trial failed to translate the promising results of
reduced brain infarction from pre-clinical stroke models to
humans (21). However, from a patient and physician perspective,
neuroprotection means keeping the damage of the ischemic
stroke below the threshold of symptom manifestation (22).
For that reason, a lack of an effect on the surrogate marker
infarct growth does not outrange the clinical response and the
neuroprotective effect of theophylline should still be investigated
in more detail.
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In summary, predictive modeling using advanced machine
learning was performed to uncover potential subtle effects
on follow-up lesion volumes of theophylline as an add-on to
thrombolytic therapy in patients with acute ischemic stroke. The
predicted follow-up brain lesions for each patient virtually treated
with theophylline and placebo confirmed the volumetric results
based on the small sample sizes of the original study. Thus,
this study also confirmed the lack of neuroprotective effect of
theophylline shown in the main clinical trial and is contrary to
the results from preclinical stroke models.
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